Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Paroxysmal Hemoglobinuria: early-phase trial registry
1 of 2 indexed Paroxysmal Hemoglobinuria trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Paroxysmal Hemoglobinuria: 2 US clinical trials tracked, 1 recruiting.
Paroxysmal Hemoglobinuria is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Apellis Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition paroxysmal-hemoglobinuria
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Paroxysmal Hemoglobinuria lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Paroxysmal Hemoglobinuria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Paroxysmal Hemoglobinuria is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals
NCT04901936
Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
National Heart, Lung, and Blood Institute (NHLBI)
NCT00039923
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Paroxysmal Hemoglobinuria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Paroxysmal Hemoglobinuria trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Paroxysmal Hemoglobinuria page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Paroxysmal Hemoglobinuria trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Apellis Pharmaceuticals sponsors the most Paroxysmal Hemoglobinuria trials on record, review their full trial history before evaluating a specific study. See Apellis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Paroxysmal Hemoglobinuria condition card totals 2 registered trials; most-linked intervention Pegcetacoplan; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.